MXPA04006210A - Composiciones acuosas que contienen metronidazole. - Google Patents

Composiciones acuosas que contienen metronidazole.

Info

Publication number
MXPA04006210A
MXPA04006210A MXPA04006210A MXPA04006210A MXPA04006210A MX PA04006210 A MXPA04006210 A MX PA04006210A MX PA04006210 A MXPA04006210 A MX PA04006210A MX PA04006210 A MXPA04006210 A MX PA04006210A MX PA04006210 A MXPA04006210 A MX PA04006210A
Authority
MX
Mexico
Prior art keywords
compositions containing
aqueous compositions
metronidazole
containing metronidazole
cyclodextrin
Prior art date
Application number
MXPA04006210A
Other languages
English (en)
Inventor
Chang Yunik
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21872727&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04006210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Publication of MXPA04006210A publication Critical patent/MXPA04006210A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
    • C08J2301/02—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una solucion acuosa de metronidazole en la - cual la concentracion de metronidazole es mayor al 0.75%. La solucion contiene una combinacion de agentes mejoradores de - solubilidad, uno de los cuales es una ciclodextrina, tal como beta-ciclodextrina y el segundo es un compuesto distinto a la ciclodextrina. Se dan a conocer tambien metodos de elaboracion y uso terapeutico de la solucion.
MXPA04006210A 2001-12-24 2002-11-07 Composiciones acuosas que contienen metronidazole. MXPA04006210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/033,835 US6881726B2 (en) 2001-12-24 2001-12-24 Aqueous compositions containing metronidazole
PCT/US2002/036063 WO2003057135A2 (en) 2001-12-24 2002-11-07 Aqueous compositions containing metronidazole

Publications (1)

Publication Number Publication Date
MXPA04006210A true MXPA04006210A (es) 2005-05-17

Family

ID=21872727

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006210A MXPA04006210A (es) 2001-12-24 2002-11-07 Composiciones acuosas que contienen metronidazole.

Country Status (20)

Country Link
US (4) US6881726B2 (es)
EP (3) EP1467744B1 (es)
JP (1) JP4611632B2 (es)
KR (1) KR100718858B1 (es)
CN (1) CN100411624C (es)
AR (1) AR037755A1 (es)
AT (1) ATE481105T1 (es)
AU (1) AU2002340458B2 (es)
BR (1) BRPI0215331B8 (es)
CA (1) CA2470492C (es)
CY (1) CY1111095T1 (es)
DE (1) DE60237710D1 (es)
DK (1) DK1467744T3 (es)
ES (1) ES2352656T3 (es)
HK (1) HK1071514A1 (es)
MX (1) MXPA04006210A (es)
PT (1) PT1467744E (es)
RU (2) RU2284810C2 (es)
WO (1) WO2003057135A2 (es)
ZA (1) ZA200405059B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
DE10306453A1 (de) * 2003-02-17 2004-08-26 Deutsche Telekom Ag Administrator
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US9446226B2 (en) * 2005-12-07 2016-09-20 Ramot At Tel-Aviv University Ltd. Drug-delivering composite structures
JP2010520897A (ja) * 2007-03-12 2010-06-17 ディーエスエム アイピー アセッツ ビー．ブイ． 化粧品組成物
US20080287513A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287514A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080312304A1 (en) * 2007-06-13 2008-12-18 Jerry Zhang Topical compositions containing metronidazole
WO2009031577A1 (ja) * 2007-09-04 2009-03-12 Meiji Seika Kaisha, Ltd. 注射剤、注射液および注射用キット製剤
AR061947A1 (es) * 2008-01-08 2008-08-10 Oscar Belluscio Daniel Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20110091515A1 (en) * 2008-06-12 2011-04-21 Ramot At Tel-Aviv University Ltd. Drug-eluting medical devices
US8729108B2 (en) * 2008-06-17 2014-05-20 Christopher J Dannaker Waterborne topical compositions for the delivery of active ingredients such as azelaic acid
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
EP2201930A1 (en) 2008-12-23 2010-06-30 Intendis GmbH Hydrogel composition for the treatment of dermatological disorders
AU2010237599A1 (en) * 2009-04-14 2011-12-08 Medortus (Uk) Ltd Gel compositions for administration of pharmaceutically active compounds
CA2822995C (en) * 2010-12-31 2021-05-11 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
CN105903028B (zh) * 2010-12-31 2020-10-16 东塘实验室有限公司 含有环糊精的细胞水合组合物
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
CA2825417A1 (en) 2011-01-25 2012-08-02 The Procter And Gamble Company Liposome and personal care composition comprising thereof
BR112013033759B1 (pt) 2011-06-28 2021-05-25 Chemo Research Sl forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
JP2015044850A (ja) * 2014-11-07 2015-03-12 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
US9492374B2 (en) * 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers
RU2020122841A (ru) 2017-12-15 2022-01-18 Тарсус Фармасьютикалс, Инк. Изоксазолиновые паразитицидные составы и способы лечения блефарита
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CN111840632A (zh) * 2019-04-25 2020-10-30 广东泰宝医疗科技股份有限公司 一种含止血微囊的液体敷料及其制备方法
US20230218657A1 (en) * 2020-06-02 2023-07-13 National University Of Singapore Compositions, their uses in therapy and methods thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) * 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
TW200402B (es) 1990-08-13 1993-02-21 Senju Pharma Co
EP0605428B9 (en) 1991-06-24 2003-01-02 hCell Technology, Inc. Hormone-secreting pancreatic cells maintained in long-term culture
US5747341A (en) 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US5708023A (en) * 1994-03-28 1998-01-13 The Trustees Of Columbia University In The City Of New York Zinc gluconate gel compositions
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ZA987800B (en) * 1997-08-27 1999-06-09 Hexal Ag Pharmaceutical composition of meloxicam
US6017516A (en) * 1997-10-31 2000-01-25 Lekar Pharma Limited Pharmaceutical dental formulation for topical application of metronidazole benzoate and chlorhexidine gluconate
US6183766B1 (en) 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
CN1116038C (zh) * 2000-11-18 2003-07-30 雷文彬 一种治疗痤疮的外用药液

Also Published As

Publication number Publication date
AR037755A1 (es) 2004-12-01
HK1071514A1 (en) 2005-07-22
AU2002340458B2 (en) 2007-01-04
WO2003057135A2 (en) 2003-07-17
US20100048659A1 (en) 2010-02-25
KR20040075911A (ko) 2004-08-30
RU2004122696A (ru) 2005-03-20
EP2238980A1 (en) 2010-10-13
WO2003057135A3 (en) 2003-12-18
BRPI0215331B1 (pt) 2015-07-28
EP1467744A4 (en) 2006-07-05
US6881726B2 (en) 2005-04-19
KR100718858B1 (ko) 2007-05-16
RU2284810C2 (ru) 2006-10-10
JP4611632B2 (ja) 2011-01-12
EP1467744B1 (en) 2010-09-15
CN1649603A (zh) 2005-08-03
DK1467744T3 (da) 2010-12-20
AU2002340458A1 (en) 2003-07-24
BR0215331A (pt) 2005-05-10
US20050124578A1 (en) 2005-06-09
RU2006116252A (ru) 2007-12-10
CN100411624C (zh) 2008-08-20
US7348317B2 (en) 2008-03-25
PT1467744E (pt) 2010-11-30
US20080154030A1 (en) 2008-06-26
BRPI0215331B8 (pt) 2021-05-25
ZA200405059B (en) 2005-09-28
CA2470492C (en) 2010-02-23
US20030119783A1 (en) 2003-06-26
DE60237710D1 (de) 2010-10-28
ES2352656T3 (es) 2011-02-22
CA2470492A1 (en) 2003-07-17
EP2241320A1 (en) 2010-10-20
CY1111095T1 (el) 2015-06-11
JP2005532990A (ja) 2005-11-04
RU2413501C2 (ru) 2011-03-10
EP1467744A2 (en) 2004-10-20
ATE481105T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
MXPA04006210A (es) Composiciones acuosas que contienen metronidazole.
ATE267145T1 (de) Mikronisiertes bariumsulfat
MXPA03011006A (es) Compuestos de cicloalquil urea benzo-fusionados 1,4-disustituidos.
HUP0203699A2 (en) A topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
HK1079519A1 (en) Furyl compounds
RS20050769A (en) Derivatives of 2-acylamino-4- phenylthiazole,preparation method thereof and application of same in therapeutics
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
HK1059055A1 (en) Complex of modafinil and cyclodextrin
AU6362100A (en) Derivatized polyurethane compositions and methods of making
MXPA04001686A (es) Combinaciones de productos activos fungicidas.
MXPA05012753A (es) Composiciones cosmeticas estables que comprenden un agente autobronceador.
ATE534384T1 (de) Verbindungen mit proliferationshemmenden eigenschaften
MY133507A (en) New peroxy-carboxylic acid and aqueous compositions thereof
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
TW200517117A (en) Stabilized compositions containing an oxygen-labile active agent
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
MXPA03011128A (es) Composicion de sabor y fragancia.
WO1999060859A8 (es) Composicion desinfectante
AU2001251005A1 (en) Ozonated solutions of tetrasilver tetroxide
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
IL162043A0 (en) Methods for killing spores
AU2001282238A1 (en) Dihydroporphyrin derivatives and their uses
AU2003221507A1 (en) Composition containing organopolysiloxanes, method for the production thereof and use of the same
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
EP1436279B8 (en) Chemical compounds

Legal Events

Date Code Title Description
FG Grant or registration